Pulmonx Reports Q1 2026 Earnings with Revenue Decline and Margin Improvement
Pulmonx (LUNG) reported Q1 2026 earnings with total revenue of $20.6 million, down 9% year-over-year, driven by declines in both U.S. and international markets. However, the company saw an improvement in gross margin to 78% and reduced operating expenses by 6% year-over-year. The international revenue decline was primarily attributed to the absence of distributor sales in China.
Tickers: $LUNG
Topics: earnings report international markets restructuring charges revenue decline